Cargando…
The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database
BACKGROUND: This study aimed to investigate the role of post-mastectomy radiotherapy (PMRT) in the female aged 70 years or older diagnosed with breast cancer, which is still controversial. METHODS: This retrospective study enrolled female breast cancer women aged 70 + years following mastectomy from...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557241/ https://www.ncbi.nlm.nih.gov/pubmed/37803254 http://dx.doi.org/10.1186/s12877-023-04341-y |
_version_ | 1785117045995601920 |
---|---|
author | Lin, Jingyi Luo, Shiping Zhang, Jie Song, Chuangui |
author_facet | Lin, Jingyi Luo, Shiping Zhang, Jie Song, Chuangui |
author_sort | Lin, Jingyi |
collection | PubMed |
description | BACKGROUND: This study aimed to investigate the role of post-mastectomy radiotherapy (PMRT) in the female aged 70 years or older diagnosed with breast cancer, which is still controversial. METHODS: This retrospective study enrolled female breast cancer women aged 70 + years following mastectomy from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was performed to reduce covariable imbalance. A nomogram was created to predict the 1,3,5-years overall survival (OS) and divide patients into three risk groups. RESULTS: After matching, PMRT were associated with significant improvement in breast cancer-specific survival (BCSS) and OS (p < 0.001). By contrast, the BCSS and OS benefit from PMRT were not significant in patients with T1N1 tumor (BCSS: HR = 0.716, p = 0.249;OS:HR = 0.908, p = 0.572), and T2N1 tumor (BCSS:HR = 0.866, p = 0.289;OS:HR = 0.879, p = 0.166). Stratified by subtype, the HR+/HER-2- subtype and the HR-/HER-2- subtype (all p < 0.001) have a significant prolonged survival, yet not significant BCSS difference are shown in the HER-2 + tumor. In the low-risk group as determined by the nomogram, the use of PMRT did not significantly improve OS (p = 0.203). CONCLUSIONS: This study demonstrated that PMRT improves the survival of females with elderly breast cancer, while for T1-2N1 breast cancer patients, the omission of PMRT could be considered. Furthermore, the nomogram we constructed could be used as a decision tool for the omission of PMRT in low-risk elderly patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-023-04341-y. |
format | Online Article Text |
id | pubmed-10557241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105572412023-10-07 The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database Lin, Jingyi Luo, Shiping Zhang, Jie Song, Chuangui BMC Geriatr Research BACKGROUND: This study aimed to investigate the role of post-mastectomy radiotherapy (PMRT) in the female aged 70 years or older diagnosed with breast cancer, which is still controversial. METHODS: This retrospective study enrolled female breast cancer women aged 70 + years following mastectomy from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was performed to reduce covariable imbalance. A nomogram was created to predict the 1,3,5-years overall survival (OS) and divide patients into three risk groups. RESULTS: After matching, PMRT were associated with significant improvement in breast cancer-specific survival (BCSS) and OS (p < 0.001). By contrast, the BCSS and OS benefit from PMRT were not significant in patients with T1N1 tumor (BCSS: HR = 0.716, p = 0.249;OS:HR = 0.908, p = 0.572), and T2N1 tumor (BCSS:HR = 0.866, p = 0.289;OS:HR = 0.879, p = 0.166). Stratified by subtype, the HR+/HER-2- subtype and the HR-/HER-2- subtype (all p < 0.001) have a significant prolonged survival, yet not significant BCSS difference are shown in the HER-2 + tumor. In the low-risk group as determined by the nomogram, the use of PMRT did not significantly improve OS (p = 0.203). CONCLUSIONS: This study demonstrated that PMRT improves the survival of females with elderly breast cancer, while for T1-2N1 breast cancer patients, the omission of PMRT could be considered. Furthermore, the nomogram we constructed could be used as a decision tool for the omission of PMRT in low-risk elderly patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-023-04341-y. BioMed Central 2023-10-06 /pmc/articles/PMC10557241/ /pubmed/37803254 http://dx.doi.org/10.1186/s12877-023-04341-y Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lin, Jingyi Luo, Shiping Zhang, Jie Song, Chuangui The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database |
title | The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database |
title_full | The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database |
title_fullStr | The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database |
title_full_unstemmed | The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database |
title_short | The trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on SEER database |
title_sort | trade-off of post-mastectomy radiotherapy usage for the breast cancer patients aged 70 years or older: a study based on seer database |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557241/ https://www.ncbi.nlm.nih.gov/pubmed/37803254 http://dx.doi.org/10.1186/s12877-023-04341-y |
work_keys_str_mv | AT linjingyi thetradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase AT luoshiping thetradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase AT zhangjie thetradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase AT songchuangui thetradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase AT linjingyi tradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase AT luoshiping tradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase AT zhangjie tradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase AT songchuangui tradeoffofpostmastectomyradiotherapyusageforthebreastcancerpatientsaged70yearsorolderastudybasedonseerdatabase |